Pfizer is getting up to $1.5 billion from Blackstone to develop berobenatide, an experimental monthly GLP-1 weight-loss drug. Pfizer keeps control of the program, but Blackstone can collect milestone payments if the drug wins U.S. approval and reaches agreed sales targets. The size of those payments has not been disclosed.
Got a news tip or correction? Let us know
If you got something out of this, please chip in to keep this site running, or subscribe to go ad-free.
2 views